New pain block could keep hip surgery patients comfortable for days
NCT ID NCT07643792
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single injection of a slow-release painkiller (liposomal bupivacaine) into a nerve block can control pain for up to 72 hours after hip fracture surgery in older adults. The standard drug only lasts about 12 hours, often leading to more pain and opioid use. The trial will compare pain scores and opioid consumption in 148 patients aged 55 and older.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal bupivacaine
What this could lead to
If it works, this could provide better pain control for up to 72 hours after hip surgery, reducing the need for opioids and lowering complication risks in older patients.
What could go wrong
This is a small, early-phase trial (148 participants) comparing two types of nerve blocks, so results may not apply broadly. The long-acting drug may not prove significantly better than the standard short-acting one.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTOPERATIVE PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••